MedTrace Logo

Potential Role of Donor-derived Cell-Free DNA as a Biomarker in Cardiac Allograft Vasculopathy

NCT04791852 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 94

Last updated 2021-09-16

No results posted yet for this study

Summary

Cross-sectional study. We will prospectively obtain ddcf-DNA levels in all patients who undergo routine coronary angiography \> 1 year after HT. Our main goal is to evaluate the performance of Donor-derived Cell Free DNA (ddcf-DNA) as a biomarker of CAV.

Conditions

  • Cardiac Allograft Vasculopathy

Interventions

DIAGNOSTIC_TEST

Donor-derived Cell Free DNA

We will compare ddcfDNA with coronary angiogram determined CAV grading, according to ISHTL2010 classification

Sponsors & Collaborators

  • Puerta de Hierro University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-10
Primary Completion
2021-01-31
Completion
2021-04-15

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04791852 on ClinicalTrials.gov